PEDIATRICS Vol. 95 No. 4 April 1995, pp. 468-474
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kappas, A.
Right arrow Articles by Valaes, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kappas, A.
Right arrow Articles by Valaes, T.

Direct Comparison of Sn-Mesoporphyrin, An Inhibitor of Bilirubin Production, and Phototherapy in Controlling Hyperbilirubinemia in Term and Near-Term Newborns

Attallah Kappas MD1, George S. Drummond PhD1, Claudia Henschke MD1, and Timos Valaes MD2

1 Rockefeller University Hospital, New York
2 New England Medical Center, Boston, The Metera Maternity Hospital, Athens, Greece

Background. Sn-mesoporphyrin (SnMP) is a potent inhibitor of bilirubin production. In our previous studies a single dose (6 µmol/kg birth weight) significantly moderated hyperbilirubinemia and reduced phototherapy (PT) time by >75% when administered within 24 hours of birth to preterm infants.

Objective. To directly compare the efficacy of SnMP and PT for controlling hyperbilirubinemia in term and near-term infants.

Methods. Two randomized, sequentially analyzed trials (Study I: male term infants; Study II: infants of both sexes and gestational age [GA] 245-265 days) were conducted. SnMP (6 µmol/kg birth weight) or PT (Phillips F20T12/BB lamps) was administered to paired infants according to strict criteria of plasma bilirubin levels and age. Time of enrollment and closure of cases and crossover, if necessary, of SnMP infants to PT or all infants to exchange transfusion were precisely defined in each pair. SnMP or PT was considered superior if the time between enrollment and closure of the case was reduced by >24 hours over the alternative treatment or if crossover had occurred.

Results. None of the 44 SnMP-treated infants required supplemental PT. Of the 22 pairs of term infants enrolled in Study I, SnMP proved superior to PT in 20 and equal in two. Of the 20 pairs of near-term infants enrolled in Study II, SnMP was superior in 12 and PT in two; six were tied. Two SnMP-treated infants were unpaired. The PT-treated infants in Study I required an average of 33 hours of treatment; those in Study II, 48 hours. None of the enrolled infants required exchange transfusion or interruption of breast-feeding.

In both studies, times between case enrollment and closure were reduced by >30 hours in SnMP compared with PT infants; requirements for additional days of medical observation and bilirubin measurements were also significantly less in SnMP infants.

Conclusion. A single dose of SnMP entirely supplanted the need for PT in jaundiced term and near-term newborns and significantly reduced medical resource use to monitor hyperbilirubinemia.

Submitted on November 14, 1994
Accepted on February 3, 1995




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
N. G. Abraham and A. Kappas
Pharmacological and Clinical Aspects of Heme Oxygenase
Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
R. J. Wong, V. K. Bhutani, H. J. Vreman, and D. K. Stevenson
Pharmacology Review: Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia
NeoReviews, February 1, 2007; 8(2): e77 - e84.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Subcommittee on Hyperbilirubinemia
Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
Pediatrics, July 1, 2004; 114(1): 297 - 316.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. U. Sarici, M. A. Serdar, A. Korkmaz, G. Erdem, O. Oran, G. Tekinalp, M. Yurdakok, and S. Yigit
Incidence, Course, and Prediction of Hyperbilirubinemia in Near-Term and Term Newborns
Pediatrics, April 1, 2004; 113(4): 775 - 780.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. Kappas
A Method for Interdicting the Development of Severe Jaundice in Newborns by Inhibiting the Production of Bilirubin
Pediatrics, January 1, 2004; 113(1): 119 - 123.
[Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
M J Maisels and J F Watchko
Treatment of jaundice in low birthweight infants
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2003; 88(6): F459 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
F. A. D. T. G. Wagener, H.-D. Volk, D. Willis, N. G. Abraham, M. P. Soares, G. J. Adema, and C. G. Figdor
Different Faces of the Heme-Heme Oxygenase System in Inflammation
Pharmacol. Rev., September 1, 2003; 55(3): 551 - 571.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. F. Sah, H. Ito, B. K. Kolli, D. A. Peterson, S. Sassa, and K.-P. Chang
Genetic Rescue of Leishmania Deficiency in Porphyrin Biosynthesis Creates Mutants Suitable for Analysis of Cellular Events in Uroporphyria and for Photodynamic Therapy
J. Biol. Chem., April 19, 2002; 277(17): 14902 - 14909.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Quan, L. Yang, N. G. Abraham, and A. Kappas
Regulation of human heme oxygenase in endothelial cells by using sense and antisense retroviral constructs
PNAS, October 9, 2001; 98(21): 12203 - 12208.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. Kappas, G. S. Drummond, and T. Valaes
A Single Dose of Sn-Mesoporphyrin Prevents Development of Severe Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-Deficient Newborns
Pediatrics, July 1, 2001; 108(1): 25 - 30.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. K. Stevenson, A. A. Fanaroff, M. J. Maisels, B. W. Y. Young, R. J. Wong, H. J. Vreman, J. R. MacMahon, C. Y. Yeung, D. S. Seidman, R. Gale, et al.
Prediction of Hyperbilirubinemia in Near-Term and Term Infants
Pediatrics, July 1, 2001; 108(1): 31 - 39.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. A. Dennery, D. S. Seidman, and D. K. Stevenson
Neonatal Hyperbilirubinemia
N. Engl. J. Med., February 22, 2001; 344(8): 581 - 590.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Rattan and S. Chakder
Influence of Heme Oxygenase Inhibitors on the Basal Tissue Enzymatic Activity and Smooth Muscle Relaxation of Internal Anal Sphincter
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1009 - 1016.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
R. F. Labbe, H. J. Vreman, and D. K. Stevenson
Zinc Protoporphyrin: A Metabolite with a Mission
Clin. Chem., December 1, 1999; 45(12): 2060 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. Kaplan, C. Hammerman;, T. Valaes, G. S. Drummond, and A. Kappas
Control of Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-Deficient Newborns
Pediatrics, February 1, 1999; 103(2): 536 - 536.
[Full Text]

Home page
 PediatricsHome page
J. C. Martinez, H. O. Garcia, L. E. Otheguy, G. S. Drummond, and A. Kappas
Control of Severe Hyperbilirubinemia in Full-term Newborns With the Inhibitor of Bilirubin Production Sn-Mesoporphyrin
Pediatrics, January 1, 1999; 103(1): 1 - 5.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. Valaes, G. S. Drummond, and A. Kappas
Control of Hyperbilirubinemia in Glucose-6-Phosphate Dehydrogenase-deficient Newborns Using an Inhibitor of Bilirubin Production, Sn-Mesoporphyrin
Pediatrics, May 1, 1998; 101 (5): e1 - e1.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. D. Lutton, N. G. Abraham, G. S. Drummond, R. D. Levere, and A. Kappas
Zinc porphyrins: Potent inhibitors of hematopoieses in animal and human bone marrow
PNAS, February 18, 1997; 94(4): 1432 - 1436.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
NEW TREATMENT FOR NEONATAL HYPERBILIRUBINEMIA
Journal Watch (General), April 18, 1995; 1995(418): 1 - 1.
[Full Text]